Atlas Trials

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

Clinical trial NCT05823987 · UNKNOWN

Trial details

NCT number
NCT05823987
Sponsor
Fudan University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Biliary Tract Cancer
Start date
2023-05-16
Primary completion
2025-12-30
Enrollment
25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.